Table 3.

Key inclusion criteria of the first investigator-initiated trial at XHH BNCT Center.

1. All patients must meet the following requirements: A. Age between 18 and 80 years, with no gender restrictions. B. An Eastern Cooperative Oncology Group (ECOG) performance score between 0 and 2. C. The tumor-to-normal tissue boron concentration ratio (TNR) should be N > 2.5, as suggested by the L-18F-BPA-PET/CT examination. D. Expected survival time not less than 3 months.

2. Patients with recurrent refractory head and neck malignant tumors must also meet the following requirements: A. Histologically confirmed head and neck malignant tumors, including nasopharynx, nasal cavity, paranasal sinus, oropharynx, oral cavity, hypopharynx, and larynx. B. Being at stages III and IV and having failed standard treatment, being unwilling to accept standard treatment, or being unable to be treated in other ways, as per the guidelines of the Chinese Society of Clinical Oncology (CSCO). C. According to RECIST1.1, at least one assessable tumor lesion.

3. Patients with primary malignant brain tumors must also meet the following requirements: A. Histologically confirmed primary malignant brain tumors, CNS WHO Grade III or Grade IV. B. Patients with measurable lesions according to the RANO (2010) standards.